Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Feb;65(2):229–233. doi: 10.1038/bjc.1992.46

In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.

G J Peters 1, I Kraal 1, H M Pinedo 1
PMCID: PMC1977736  PMID: 1739622

Abstract

Brequinar sodium (DUP-785; Brequinar) is a potent inhibitor of the pyrimidine de novo enzyme dihydroorotate dehydrogenase (DHO-DH), leading to a depletion of pyrimidine nucleotides, which could be reversed by uridine. In in vitro studies we investigated the effect of different physiological concentrations of uridine on the growth-inhibition by Brequinar, the effect of the nucleoside transport inhibitor, dipyridamole, and the combination of Brequinar and 5-fluorouracil (5FU). Uridine at 1 microM slightly reversed the growth inhibition by Brequinar, while the effect of 5-500 microM was greater. However, at Brequinar concentrations greater than 30 microM, uridine could not reverse the growth-inhibitory effects. Addition of dipyridamole could only partially prevent the reversing effects of uridine. The combination of Brequinar and 5FU was more than additive in the absence of uridine in the culture medium, but not in the presence of uridine. The combination of Brequinar and 5FU was tested in vivo in two murine colon tumour models, Colon 26 and Colon 38. Scheduling of both compounds appeared to be very important. In Colon 38 no potentiating effect of Brequinar could be observed. In contrast in Colon 26 a more than additive effect could be observed. Since uridine concentrations are considerably different in these tumours (higher in Colon 38), it was concluded from both the in vitro and in vivo experiments that uridine is an important determinant in combinations of Brequinar and 5FU.

Full text

PDF
229

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson L. W., Strong J. M., Cysyk R. L. Cellular pharmacology of DUP-785, a new anticancer agent. Cancer Commun. 1989;1(6):381–387. doi: 10.3727/095535489820875101. [DOI] [PubMed] [Google Scholar]
  2. Arbuck S. G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer. 1989 Mar 15;63(6 Suppl):1036–1044. doi: 10.1002/1097-0142(19890315)63:6+<1036::aid-cncr2820631309>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  3. Arteaga C. L., Brown T. D., Kuhn J. G., Shen H. S., O'Rourke T. J., Beougher K., Brentzel H. J., Von Hoff D. D., Weiss G. R. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390). Cancer Res. 1989 Aug 15;49(16):4648–4653. [PubMed] [Google Scholar]
  4. Bork E., Vest S., Hansen H. H. A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule. Eur J Cancer Clin Oncol. 1989 Oct;25(10):1403–1411. doi: 10.1016/0277-5379(89)90097-7. [DOI] [PubMed] [Google Scholar]
  5. Braakhuis B. J., van Dongen G. A., Peters G. J., van Walsum M., Snow G. B. Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts. Cancer Lett. 1990 Feb;49(2):133–137. doi: 10.1016/0304-3835(90)90149-r. [DOI] [PubMed] [Google Scholar]
  6. Casper E. S., Vale K., Williams L. J., Martin D. S., Young C. W. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid. Cancer Res. 1983 May;43(5):2324–2329. [PubMed] [Google Scholar]
  7. Chen S. F., Ruben R. L., Dexter D. L. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res. 1986 Oct;46(10):5014–5019. [PubMed] [Google Scholar]
  8. Darnowski J. W., Handschumacher R. E. Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake. Cancer Res. 1986 Jul;46(7):3490–3494. [PubMed] [Google Scholar]
  9. Dexter D. L., Hesson D. P., Ardecky R. J., Rao G. V., Tippett D. L., Dusak B. A., Paull K. D., Plowman J., DeLarco B. M., Narayanan V. L. Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors. Cancer Res. 1985 Nov;45(11 Pt 1):5563–5568. [PubMed] [Google Scholar]
  10. Grem J. L., King S. A., O'Dwyer P. J., Leyland-Jones B. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review. Cancer Res. 1988 Aug 15;48(16):4441–4454. [PubMed] [Google Scholar]
  11. Keepers Y. P., Pizao P. E., Peters G. J., van Ark-Otte J., Winograd B., Pinedo H. M. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer. 1991;27(7):897–900. doi: 10.1016/0277-5379(91)90142-z. [DOI] [PubMed] [Google Scholar]
  12. Leyland-Jones B., O'Dwyer P. J. Biochemical modulation: application of laboratory models to the clinic. Cancer Treat Rep. 1986 Jan;70(1):219–229. [PubMed] [Google Scholar]
  13. Löffler M. On the role of dihydroorotate dehydrogenase in growth cessation of Ehrlich ascites tumor cells cultured under oxygen deficiency. Eur J Biochem. 1980;107(1):207–215. doi: 10.1111/j.1432-1033.1980.tb04641.x. [DOI] [PubMed] [Google Scholar]
  14. Martin D. S., Stolfi R. L., Sawyer R. C., Spiegelman S., Casper E. S., Young C. W. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. Cancer Res. 1983 May;43(5):2317–2321. [PubMed] [Google Scholar]
  15. Martin D. S., Stolfi R. L., Sawyer R. C., Young C. W. Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy. Cancer Treat Rep. 1985 Apr;69(4):421–423. [PubMed] [Google Scholar]
  16. Noe D. A., Rowinsky E. K., Shen H. S., Clarke B. V., Grochow L. B., McGuire W. B., Hantel A., Adams D. B., Abeloff M. D., Ettinger D. S. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390). Cancer Res. 1990 Aug 1;50(15):4595–4599. [PubMed] [Google Scholar]
  17. O'Dwyer P. J., Paul A. R., Walczak J., Weiner L. M., Litwin S., Comis R. L. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol. 1990 Sep;8(9):1497–1503. doi: 10.1200/JCO.1990.8.9.1497. [DOI] [PubMed] [Google Scholar]
  18. Peters G. J., Nadal J. C., Laurensse E. J., de Kant E., Pinedo H. M. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer. Biochem Pharmacol. 1990 Jan 1;39(1):135–144. doi: 10.1016/0006-2952(90)90657-7. [DOI] [PubMed] [Google Scholar]
  19. Peters G. J., Schwartsmann G., Nadal J. C., Laurensse E. J., van Groeningen C. J., van der Vijgh W. J., Pinedo H. M. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients. Cancer Res. 1990 Aug 1;50(15):4644–4649. [PubMed] [Google Scholar]
  20. Peters G. J., Sharma S. L., Laurensse E., Pinedo H. M. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390). Invest New Drugs. 1987;5(3):235–244. doi: 10.1007/BF00175293. [DOI] [PubMed] [Google Scholar]
  21. Peters G. J., van Groeningen C. J., Laurensse E. J., Lankelma J., Leyva A., Pinedo H. M. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. Cancer Chemother Pharmacol. 1987;20(2):101–108. doi: 10.1007/BF00253962. [DOI] [PubMed] [Google Scholar]
  22. Schwartsmann G., Dodion P., Vermorken J. B., ten Bokkel Huinink W. W., Joggi J., Winograd B., Gall H., Simonetti G., van der Vijgh W. J., van Hennik M. B. Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies. Cancer Chemother Pharmacol. 1990;25(5):345–351. doi: 10.1007/BF00686235. [DOI] [PubMed] [Google Scholar]
  23. Schwartsmann G., Peters G. J., Laurensse E., de Waal F. C., Loonen A. H., Leyva A., Pinedo H. M. DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects. Biochem Pharmacol. 1988 Sep 1;37(17):3257–3266. doi: 10.1016/0006-2952(88)90636-3. [DOI] [PubMed] [Google Scholar]
  24. Shen H. S., Chen S. F., Behrens D. L., Whitney C. C., Dexter D. L., Forbes M. Distribution of the novel anticancer drug candidate Brequinar sodium (DuP 785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenografts. Cancer Chemother Pharmacol. 1988;22(3):183–186. doi: 10.1007/BF00273407. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES